Course handouts are now available
Click here
Come to London
WATCH to find out why
Site updates:
Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.
Posters
(results will display both Free Papers & Poster)
Assessment of corneal aberration and elevation changes after pterygium surgery
Poster Details
First Author: I.Omar EGYPT
Co Author(s):
Abstract Details
Purpose:
To assess the changes in corneal higher order aberrations and changes in the elevation of the front and back corneal surfaces using the oculus pentacam
Setting:
Data were taken from a prospective study included 63 eyes of 50 patients with primary pterygium between December 2012 and November 2013 in Elminya university hospital.
Methods:
All patients had pterygium excision with conjunctival autograft and intraoperative application of mitomycin C 0.5%. Patients examined with oculus pentacam to assess the corneal aberrations and elevation induced by pterygium preoperatively and six months after its excision.
Results:
Eight eyes were in female patients and fifty five in male patients. The mean age was 47.2±5.3 (ranging from 38 to 56 years). The root mean square (RMS) of total and higher order aberrations decreased postoperatively except for the spherical aberration which increased (0.43±0.17µm versus 0.26±0.2µm, p=0.001). The RMS of postoperative coma and trefoil decreased significantly (-0.01±0.2µm versus 0.06±0.4 µm p=0.03 for coma) and (-0.07±0.6µm vs -0.15±0.3µm, p=0.04 for trefoil). Analysis of the corneal elevation revealed that the front and back elevations decreased significantly six months postoperatively at the 7mm zone (-68.1±25.1mm versus - 44.8±46.6mm p=0.001 for the front), and (-157.07± 117.8mm versus -198.43 ± 66.5mm p= 0.017 for the back).
Conclusions:
Pterygium affects the corneal surface and induces elevation changes and aberrations that is why it should be removed to improve the visual performance of the patients and so pterygium excision should be taken into consideration before cataract and refractive surgeries planned for those patients. FINANCIAL INTEREST: NONE